Floatz logo

(+)-Vincristine

B-Cell Non-Hodgkin Lymphoma

Explore 306 assets in B-Cell Non-Hodgkin Lymphoma →
Floatz Rating
BB69/100
Confidence
Indicative
v0.2
Sponsor
Mwanasha Merrill, MD
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07588698CT.gov
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
—Not Yet Recruiting———
NCT07081022CT.gov
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
—Recruiting———
NCT07168980CT.gov
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
—Recruiting———
NCT06564038CT.gov
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
—Recruiting———
NCT05583149CT.gov
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
—Active Not Recruiting———
NCT05270057CT.gov
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
—Active Not Recruiting———
NCT05476770CT.gov
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
—Recruiting———
NCT05518383CT.gov
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
—Recruiting———
NCT05201248CT.gov
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
—Active Not Recruiting———
NCT04220008CT.gov
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
—Withdrawn———
Show 28 more trials
NCT04884035CT.gov
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
—Recruiting———
NCT05097443CT.gov
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
—Unknown———
NCT05164770CT.gov
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
—Unknown———
NCT04257578CT.gov
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
—Active Not Recruiting———
NCT03995147CT.gov
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
—Active Not Recruiting———
NCT04094142CT.gov
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
—Completed———
NCT04152577CT.gov
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
—Unknown———
NCT03677141CT.gov
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
—Completed———
NCT03467373CT.gov
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
—Completed———
NCT03206671CT.gov
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
—Active Not Recruiting———
NCT02670317CT.gov
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
—Terminated———
NCT02787239CT.gov
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
—Completed———
NCT02405676CT.gov
BNHL-2015 for Children or Adolescents in China
—Active Not Recruiting———
NCT01925612CT.gov
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
—Terminated———
NCT01897012CT.gov
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
—Completed———
NCT01789255CT.gov
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
—Completed———
NCT01695941CT.gov
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
—Active Not Recruiting———
NCT01516580CT.gov
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
—Completed———
NCT01414855CT.gov
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
—Completed———
NCT00992446CT.gov
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
—Completed———
NCT01055496CT.gov
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
—Completed———
NCT00764517CT.gov
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
—Completed———
NCT00498043CT.gov
A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
—Completed———
NCT00455897CT.gov
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
—Terminated———
NCT00379574CT.gov
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
—Completed———
NCT00054665CT.gov
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
—Completed———
NCT00147121CT.gov
Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)
—Completed———
NCT00051025CT.gov
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · B-Cell Non-Hodgkin Lymphoma

AssetSponsorPhaseRating
(+)-Vincristine (this asset)Mwanasha Merrill, MDApprovedBB · 69
VindesineChildren's Cancer Group, ChinaP4BBB
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamP3BBB
CytarabineChildren's Cancer Group, ChinaP4BBB
ZanubrutinibThe First Affiliated Hospital of Soochow UniversityP4BBB
CamustineFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyP4BBB
IsocyclophosphamideShanghai Junshi Bioscience Co., Ltd.P4BBB
Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Transduced With A Nonreplicative Self-Inactivating (Sin) Lentiviral Vector Encoding A Chimeric Antigen Receptor (Car) Consisting Of The Human Cd19-Specific Scfv, An Lgg4 Hinge Region, Cd28 Transmembrane Domain, Cd137 (4-1Bb) Co-Stimulatory Domain And Cd3 Zeta Signalling Domain, Under The Control Of A Hybrid Elongation Factor 1 Alpha (Ef1.Alpha.) And Human T Cell Leukemia Virus Type 1(Htlv-1) Regulatory Element Promoter And Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (Wpre). The Vector Genome Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Co-Expressed With The Car And Cleaved From It By The T2A Self-Cleaving Peptide. The Vector Genome Also Contains A Splice Donor, A Fragment Of Gag, A Rev Response Element (Rre), A Mutated Central Polypurine Tract (Cppt), And A Splice AcceptorRuijin HospitalP4BBB
cd19-ucartUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyP4BB

+42 more in the B-Cell Non-Hodgkin Lymphoma cohort

Other indications for (+)-Vincristine

IndicationSponsorPhaseRating
Mycosis Fungoides—P4BBB · 78
Anaplastic Large Cell Lymphoma—P4BBB · 78
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma—P4BBB · 77

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. (+)-Vincristine in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/vincristine-b-cell-non-hodgkin-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →